Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Abstract
Lenvatinib is an effective drug in advanced HCC. Its combination with the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed to explore the molecular and immunomodulatory effects of lenvatinib alone or in combination with anti‐PD1.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 27, 2021
- Source ID
- 10.1002/hep.32023
Entities
People
- Agavni Mesropian
- Behnam Saberi
- Carla Montironi
- Catherine E Willoughby
- Daniel Joseph Geh
- Daniela Sia
- Derek A. Mann
- Erik Ramón-Gil
- Jack Leslie
- Jordi Abril-Fornaguera
- Josep M. Llovet
- Judit Peix
- Laura Torrens
- Marc Puigvehí
- Marta Piqué‐Gili
- Miguel Torres-Martín
- Miho Maeda
- Philipp K. Haber
- Scott L. Friedman
- Ugne Balaseviciute
Organizations
- Icahn School of Medicine at Mount Sinai
- Newcastle University
- University of Barcelona